Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule.
The availability of early biological markers of renal damage is important for the identification of risk factors and for starting therapeutic intervention in the reversible phase of renal pathology. The usefulness of such markers relies upon their capacity to detect alterations in distinct nephron segments. Using specific monoclonal antibodies against the intestinal isoenzyme of alkaline phosphatase (IAP) and against the tissue-nonspecific isoenzyme (TNAP), we demonstrated that IAP expression in the human kidney is restricted to the straight part of the proximal tubule (the S3 segment), whereas TNAP is expressed mainly in the proximal convoluted tubule (the S1 and S2 segments) but also in the S3 segment. This complementarity opens perspectives for IAP and TNAP as distinct proximal tubular markers, particularly for IAP, since there are no other markers available that are specific for the S3 segment. Based on these monoclonal antibodies, specific and easy to use enzyme-antigen immunoassay (EAIA) procedures were developed to detect IAP and TNAP in human urine samples. The detection limits are below the lowest enzyme activities found in the urine of normal subjects, the intra- and inter-assay variability is low, the analytical recovery approaches 100%, and EAIA enzyme activity values correlate with ELISA immunoreactivity values. Furthermore, easy urine sample preconditioning allows antigen preservation over an extended time period at 4 degrees and -80 degrees C. Using these assays, it could be demonstrated in more than 20 occupationally and environmentally exposed cohorts and clinical patient groups that urinary IAP is indeed a marker of early alterations in the S3 segment, and that it behaves largely independently from urinary TNAP.(ABSTRACT TRUNCATED AT 250 WORDS)
Nouwen
E J
EJ
Department Nephrology, University of Antwerp, Belgium.
De Broe
M E
ME
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000652:urine*; D015415:Biomarkers / Q000652:urine; D002945:Cisplatin / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000201:enzymology; D004795:Enzyme Stability; D005260:Female; D006801:Humans; D007422:Intestines / Q000201:enzymology*; D007527:Isoenzymes / Q000652:urine*; D007677:Kidney Function Tests / Q000379:methods; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000201:enzymology*; D007854:Lead / Q000009:adverse effects; D008297:Male; D008628:Mercury / Q000009:adverse effects; D008875:Middle Aged; D016273:Occupational Exposure; D009928:Organ Specificity
D015415:Biomarkers; D007527:Isoenzymes; D007854:Lead; D000469:Alkaline Phosphatase; D008628:Mercury; D002945:Cisplatin